Cargando…

Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer

(1) Objective: Late-line chemotherapy rechallenge in recurrent cervical cancer is associated with modest therapy response but significant side effects. As mTOR pathways modulate cellular growth via estrogen receptor (ER) signaling and combined mTOR and ER inhibition previously demonstrated survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartl, Thomas, Grimm, Christoph, Mader, Robert M., Zielinski, Christoph, Prager, Gerald, Unseld, Matthias, Herac-Kornauth, Merima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455725/ https://www.ncbi.nlm.nih.gov/pubmed/37623437 http://dx.doi.org/10.3390/jpm13081186

Ejemplares similares

Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior
por: Bianconi, Daniela, et al.
Publicado: (2022)

SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment
por: Bianconi, Daniela, et al.
Publicado: (2018)

Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
por: Bianconi, Daniela, et al.
Publicado: (2017)

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
por: Bianconi, Daniela, et al.
Publicado: (2020)

Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs: Effect of Akt/mTOR inhibition on PTEN expression
por: Wan, Linyan, et al.
Publicado: (2022)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior
por: Poettler, Marina, et al.
Publicado: (2013)

Notoginsenoside R7 suppresses cervical cancer via PI3K/PTEN/Akt/mTOR signaling
por: Li, Li, et al.
Publicado: (2017)

Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma
por: Lu, Jianjun, et al.
Publicado: (2015)

Contribution of mTOR and PTEN to Radioresistance in Sporadic and NF2-Associated Vestibular Schwannomas: A Microarray and Pathway Analysis
por: Gugel, Isabel, et al.
Publicado: (2020)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
por: Prvanović, Mirjana, et al.
Publicado: (2021)

Targeting mTOR Pathway in PTEN Deleted Newly Isolated Chordoma Cell Line
por: Pagani, Francesca, et al.
Publicado: (2023)

The mTOR pathway genes mTOR, Rheb, Depdc5, Pten, and Tsc1 have convergent and divergent impacts on cortical neuron development and function
por: Nguyen, Lena H., et al.
Publicado: (2023)

Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins
por: Ma, Jing, et al.
Publicado: (2023)

Effect of mTOR Inhibitors in Nude Mice with Endometrial Carcinoma and Variable PTEN Expression Status
por: Fong, Pedro, et al.
Publicado: (2014)

mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53
por: Jung, Seung Hee, et al.
Publicado: (2018)

YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas
por: Xu, Wei, et al.
Publicado: (2021)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

mTOR Promotes Tissue Factor Expression and Activity in EGFR-Mutant Cancer
por: Cong, Ying, et al.
Publicado: (2020)

Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT
por: Unseld, Matthias, et al.
Publicado: (2018)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Estrogen receptor β induces autophagy of osteosarcoma through the mTOR signaling pathway
por: Yang, Zhengming, et al.
Publicado: (2020)

Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
por: Prager, Gerald W, et al.
Publicado: (2014)

PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway
por: Cheng, Zhi Y, et al.
Publicado: (2008)

MAF1 suppresses AKT‐mTOR signaling and liver cancer through activation of PTEN transcription
por: Li, Yue, et al.
Publicado: (2016)

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
por: Milella, Michele, et al.
Publicado: (2017)

PTEN/AKT/mTOR signaling mediates anticancer effects of epigallocatechin-3-gallate in ovarian cancer
por: Qin, Jianli, et al.
Publicado: (2020)

Tripartite motif 27 promotes cardiac hypertrophy via PTEN/Akt/mTOR signal pathways
por: Chen, Yan, et al.
Publicado: (2022)

Gold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth
por: Hossen, Md. Nazir, et al.
Publicado: (2022)

Integrins in the Spotlight of Cancer
por: Bianconi, Daniela, et al.
Publicado: (2016)

The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma
por: Bassullu, Nuray, et al.
Publicado: (2012)

The Role of mTOR and eIF Signaling in Benign Endometrial Diseases
por: Driva, Tatiana S., et al.
Publicado: (2022)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR Inhibition Leads to Src-Mediated EGFR Internalisation and Degradation in Glioma Cells
por: Colella, Barbara, et al.
Publicado: (2020)

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
por: Bang, Jieun, et al.
Publicado: (2023)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Lkb1 and Pten Synergise to Suppress mTOR-Mediated Tumorigenesis and Epithelial-Mesenchymal Transition in the Mouse Bladder
por: Shorning, Boris Y., et al.
Publicado: (2011)

Genetic Variations in a PTEN/AKT/mTOR Axis and Prostate Cancer Risk in a Chinese Population
por: Chen, Jiawei, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2h2ua961cur30geftd3eokea54